Roivant Sciences

Director at Arbutus Biopharma · 2 reported transactions in 2 companies · latest trade Dec 12, 2025

Their record

Across their whole record, 1 purchase can be measured; 1 did better than the S&P 500 over the next 6 months.

Typical move +16.6%, S&P 500 +8.4% over the same days.


ImmunovantIMVT	Bought $350M · 16,666,666 shares	Dec 12, 2025	S&P 500 +13.3%thru Oct 29

Dec 12, 2025 · IMVT

$350M

S&P 500 +13.3%thru Oct 29

2 transactionsPro adds every trade with how it did, their holdings and the money-flow chartPro is $29 a month

Built from their public trade reports and market prices: past moves, not predictions or advice.